Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/007—Pulmonary tract; Aromatherapy
  • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
  • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/50—Pyridazines; Hydrogenated pyridazines
  • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
  • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/18—Growth factors; Growth regulators
  • A61K38/1858—Platelet-derived growth factor [PDGF]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/19—Cytokines; Lymphokines; Interferons
  • A61K38/193—Colony stimulating factors [CSF]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/007—Pulmonary tract; Aromatherapy
  • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/007—Pulmonary tract; Aromatherapy
  • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
  • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/12—Antihypertensives
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
  • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
  • C07B2200/13—Crystalline forms, e.g. polymorphs

Definitions

• the invention relates to inhalable imatinib formulations, manufacture, and uses thereof.
• Pulmonary arterial hypertension is a condition involving elevated blood pressure in the arteries of the lungs with unknown causes and is differentiated from systemic hypertension. PAH is a progressive disease where resistance to blood flow increases in the lungs causing damage to the lungs, the pulmonary vasculature and the heart that can eventually lead to death. While symptoms are treatable with vasodilators and other medications, there is no known disease modifying therapy or cure and advanced cases can eventually require lung transplants.
• Imatinib is a tyrosine kinase inhibitor approved for use in treating certain types of cancer.
• PDGFR platelet-derived growth factor receptor
• compositions and methods of the invention address problems with imatinib-based PAH treatments through the use of specialized formulations and delivery mechanisms.
• inhalable imatinib solutions and suspensions are provided along with methods of delivery such formulations through inhalation via a nebulizer.
• Nebulizers are drug delivery devices that aerosolize solutions and suspensions for inhalation using compressed gas.
• Formulations for nebulization may be provided in solution or suspension form. Imatinib formulations may be used with any type of nebulizer. For example, commercially available nebulizers from Vectura Group plc (UK) including jet nebulizers such as the Akita jet nebulizer and the FOX vibrating mesh nebulizer.
• nebulizers from Vectura Group plc (UK) including jet nebulizers such as the Akita jet nebulizer and the FOX vibrating mesh nebulizer.
• nebulizers contemplated for use with formulations and methods of the invention include soft mist inhalers and ultrasonic wave nebulizers.
• Methods and kits of the invention may include dehydration and reconstitution agents for dehydrating and reconstituting liquid formulations of the invention in a sterile manner for nebulization.
• formulations may comprise 50% or more imatinib or imatinib salts.
• Compositions and methods of the invention recognize that large volumes may be difficult or dangerous for patients to inhale and that, therefore, minimizing the amount of non-API components in the formulation can improve patient comfort, safety, and compliance by reducing the overall amount of compound that is inhaled while still providing a therapeutically effective API concentration in target tissue.
• compositions and methods of the invention can provide the load-reducing benefits discussed above while still delivering therapeutic results and avoiding the severe adverse events associated with other drug delivery routes.
• Nebulizer-ready formulations of the invention may comprise imatinib or salts thereof in solution or suspension form in various embodiments.
• Imatinib suspensions may comprise imatinib particles of entirely or almost entirely a single crystal form (e.g., greater than 80%, 85%, 90%, 95%, 99% or 100% of a single crystal form), thereby allowing for controlled and predictable dosing and patient response.
• greater than 95% of imatinib or a salt thereof in the inhalable formulation may be present in a single crystal form.
• inhalable imatinib compounds may be micronized through wet or dry milling (e.g., jet milling) to achieve the desired particle size for suspensions for nebulization.
• Imatinib or appropriate salts thereof may be micronized to particle sizes of about 0.5 ⁇ m to about 5 ⁇ m mass median aerodynamic diameter (MMAD).
• MMAD mass median aerodynamic diameter
• the imatinib free base may be preferred for efficient delivery of the active moiety to lung tissue.
• various excipients or carriers can be added to imatinib or salts thereof before or after micronization depending on application while maintaining a relatively high (e.g., 50% or greater) ratio of the API.
• carriers such as lecithin, distearylphosphatidylcholine (DSPC) or other lipid-based carriers, or various hydrophilic polymers where they exhibit appropriate physico-chemical properties may be included.
• DSPC distearylphosphatidylcholine
• API:carrier ratios may be greater than 50:50, 75:25, or 90:10. Additional ratios are contemplated as discussed below.
• all or most amorphous imatinib may be excluded from the formulation, even after micronization.
• crystal form can be important to drug pharmacokinetics and dosing, as well as physicochemical stability, avoiding amorphous content can also be important to providing predictable and efficient therapy.
• formulations of the invention can be used to treat various conditions of the pulmonary cardiovascular system while avoiding the adverse events associated with higher doses that are administered by other routes of administration that introduce the drug systemically prior to reaching the target tissue.
• compounds and methods of the invention can be used to treat PAH as well as lung transplant rejection, pulmonary veno-occlusive disease (PVOD) and pulmonary hypertension secondary to other diseases like heart failure with preserved ejection fraction (HFpEF) or schistosomiasis.
• Dose ranges can include between about 10 mg to about 100 mg per dose for inhalation on a twice to four times per day schedule.
• compositions of the invention can have relatively high concentrations of API (e.g., 50% or greater), the above doses can be achieved with less overall volume of inhalable compared to conventional formulations having 1%-3% API.
• formulations of the invention can include processing and administration of imatinib in free base form.
• Free base imatinib formulations of the invention can retain crystallinity after micronization.
• compounds and methods of the invention include inhalable formulations of free base imatinib.
• Methods may include providing to a subject a nebulized formulation of imatinib or a salt thereof.
• the formulation can include droplets that comprise imatinib or a salt thereof.
• the droplets may be sized between about 0.5 to about 5 ⁇ m.
• formulations may further comprise one or more excipients.
• nebulized formulations may comprise solubilized imatinib or a salt thereof in solution.
• the subject can be a mammal and, in preferred embodiments, a human.
• the condition of the pulmonary cardiovascular system may be pulmonary arterial hypertension (PAH).
• PAH pulmonary arterial hypertension
• the formulation may be nebulized using a jet nebulizer.
• the formulation may be nebulized using a vibrating mesh nebulizer.
• the invention may include a kit for treating a condition of the pulmonary cardiovascular system, comprising a liquid formulation of imatinib or a salt thereof and a nebulizer.
• the liquid formulation may be a sterile liquid formulation.
• the imatinib or a salt thereof may be a dry composition or a salt thereof and the kit may comprise one or more liquids for reconstituting the imatinib or salt thereof.
• the nebulizer may be a jet nebulizer, a vibrating mesh nebulizer, a soft mist inhaler, or an ultrasonic wave nebulizer.
• the dry composition of the imatinib or a salt thereof may include particles of imatinib or a salt thereof.
• the particles of imatinib or a salt thereof may have been micronized.
• the micronized particles may be sized about 0.5 to about 5 ⁇ m.
• the formulation may further include one or more excipients.
• the nebulizer can be operable to generate droplets of the liquid formulation sized between about 0.5 ⁇ m and about 5 ⁇ m.
• the imatinib or a salt thereof may be partitioned into two or more volumes, each of the two or more volumes corresponding to a therapeutically effective individual dose for treating the condition of the pulmonary cardiovascular system.
• Each volume the imatinib or a salt thereof can be a sterile liquid formulation.
• Kits of the invention may further include a first set of one or more agents to dehydrate the liquid formulation to produce a dried composition of the imatinib or a salt thereof and a second set of one or more agents to reconstitute the dried composition as a sterile liquid formulation of the imatinib or a salt thereof.
• aspects of the invention may include methods of treating a condition of the pulmonary cardiovascular system. Such methods may include providing imatinib or a salt thereof, reconstituting the imatinib or a salt thereof in a sterile solvent to prepare a reconstituted solution of imatinib or salt thereof, and nebulizing the reconstituted solution.
• the reconstituted solution may include one or more excipients.
• the imatinib or a salt thereof may be a liquid formulation of the imatinib or a salt thereof, and the method can first include dehydrating the liquid formulation to produce a dried composition of the imatinib or a salt thereof. Dehydrating may be accomplished using one or more dehydrating agents.
• the reconstituting step can include transferring the sterile solvent from a first to sealed container to a second sealed container comprising the imatinib or salt thereof using a needle or dispensing pin.
• Nebulizing may include coupling the second sealed container to a nebulizer.
• nebulizing can include transferring the reconstituted solution from the second sealed container to the nebulizer using a needle or a dispensing pin.
• the invention relates to inhalable formulations of imatinib and salts thereof. Specifically, inhalable formulations compatible with nebulizers for inhalation as well as methods and kits for nebulized imatinib treatments.
• Imatinib refers to the free base compound or salts thereof. Imatinib as the free base has the below structure.
• compositions described herein provide greater concentrations of imatinib in target lung tissue than obtained with equivalent doses administered orally or through IV.
• imatinib suspensions having the characteristics described herein can be delivered via inhalation using, for example, a nebulizer. While imatinib or salts thereof may be nebulized in solution, imatinib suspensions may offer advantages over solutions in certain embodiments as discussed below.
• Nebulizers use oxygen, compressed air, or ultrasonic power to break up solutions and suspensions into small aerosol droplets that can be directly inhaled by a user in need of treatment.
• Formulations and methods of the invention may use any known type of nebulizer including soft mist inhalers, jet nebulizers, ultrasonic wave nebulizers, and vibrating mesh nebulizers. Jet nebulizers and vibrating mesh nebulizers, for example, are commercially available from Vectura Group plc (UK).
• Soft mist inhalers use mechanical energy stored in a spring by user-actuation to pressurize a liquid container, causing the contained-liquid to spray out of a nozzle for inhalation in the form of a soft mist.
• Soft mist inhalers do not rely on gas propellant or electrical power for operation.
• the average droplet size in soft mist inhalers is about 5.8 micrometers.
• Jet nebulizers are the most commonly used and may be referred to as atomizers. Jet nebulizers use a compressed gas (e.g., air or oxygen) to aerosolize a liquid medicine when released therethrough at high velocity. The resulting aerosolized droplets of therapeutic solution or suspension are then inhaled by a user for treatment.
• the compressed gas may be pre-compressed in a storage container or may be compressed on-demand by a compressor in the nebulizer.
• Ultrasonic wave nebulizers rely on an electronic oscillator to generate a high frequency ultrasonic wave that, when directed through a reservoir of a therapeutic suspension of solution, aerosolized the medicine for inhalation.
• Vibrating mesh nebulizers use the vibration of a membrane having thousands of holes at the top of the liquid reservoir to aerosolize a fine-droplet mist for inhalation. Vibrating mesh nebulizers avoid some of the drawbacks of ultrasonic wave nebulizers, offering more efficient aerosolization with reduced treatment times and less heating of the liquid being nebulized.
• nebulizers used in the invention may include pulsed air flow as described in U.S. Pat. No. 7,866,317, mixed flow of aerosol and compressed gas as described in U.S. Pat. No. 8,181,644, or other nebulizer features as described in U.S. Pat. Nos. 7,647,928; 8,910,625; and 7,891,358; and U.S. Pat. Pub. No. 2015/0174343, the content of each of which is incorporated herein by reference.
• concentration of imatinib formulations may be achieved at various areas of the lung through manipulation of delayed release technology such as described in U.S. Pat. No. 8,534,277, incorporated herein by reference.
• nebulizer formulations may include particles sized and shaped as described in U.S. Pat. No. 8,101,160, or prepared using methods described in U.S. Pat. Pub. No. 2018/0257084, the content of each of which is incorporated herein by reference.
• Formulations and methods of the invention may include nebulized imatinib administered using techniques or in combination with other inhalable compounds as described in U.S. Pat. Nos. 7,928,089; 9,486,427; and 8,834,848 as well as U.S. Pat. Pub. Nos. 2017/0014424, 2016/0193434, 2010/0297030, 2013/0034534, and 2017/0304566, the content of each of which is incorporated herein by reference.
• Kits of the invention may include a nebulizer such as those described above along with an effective does of a solution or suspension of imatinib or salts thereof for treating a cardiovascular or pulmonary disease such as PAH.
• Kits may include additional materials for reconstituting dry ingredients including imatinib formulations for nebulization in a sterile manner.
• kits may include sealed containers of dry ingredients and sterile solvents (e.g., water) as well as syringes, needles, dispensing pins, mini-spikes, or other means of accessing the solvent within the sealed container and adding it to the dry ingredients. Accordingly, solutions can be reconstituted in a sterile manner and then nebulized by users as described herein.
• Dehydration and lyophilization methods and systems are well known and can be applied herein in a sterile manner to prepare formulations of imatinib or salts thereof for storage and shipment prior to reconstitution and nebulization. See Walters, et al., 2014, Next Generation Drying Technologies for Pharmaceutical Applications, Journal of Pharmaceutical Sciences 103:2673-2695, incorporated herein by reference. Commercial lyophilizers are available, for example, from SP Scientific, Warminster, Pa. Dehydration of formulations of the invention for nebulizing may be performed using any known dehydration methods or agents such as critical point drying with CO 2 under pressure, solvent substitution, vacuum, or blow drying (e.g., in a nitrogen atmosphere).
• Nebulized doses in high API ratio formulations can make up a relatively high percentage of the overall formulation, allowing them to be delivered in lower overall volumes than conventional formulations of between 1% and 3% API. Reducing the volume a patient must inhale can increase patient comfort and compliance, thereby improving results. Additionally, a higher percentage of API content can improve the API distribution and blend uniformity. Accordingly, methods and compositions of the invention allow for treatment of conditions of the pulmonary cardiovascular system (e.g., PAH) with lower doses and less inhalable volume than would be required in systemic administration, thereby lowering the risk of adverse events including subdural hematoma (See, Frost et al.). Thus, the invention provides viable treatment methods for life threatening diseases that were heretofore too risky for practical application.
• PAH pulmonary cardiovascular system
• compounds of the invention include formulations of imatinib or salts thereof.
• the free base imatinib is used in a formulation for inhalation to treat a condition of the pulmonary cardiovascular system such as PAH.
• Certain salt forms are also contemplated.
• imatinib salts that were found to exhibit suitable thermal stability and few or single polymorphic forms include glycollate, isethionate, malonate, tartrate, and malate.
• Other salt forms contemplated herein are xinafoate, furoate, trifenatate, HCl, sulfate, phosphate, lactate, maleate, fumarate, succinate, adipate, mesylate, and citrate.
• formulations can comprise at least 50% imatinib or a salt thereof.
• imatinib formulations of the invention may include one or more excipients.
• lecithin phospholipids such as DSPC may be used as an excipient for nebulized inhalation.
• excipients may include various hydrophilic polymers. See, for example, Karolewicz, B., 2016, A review of polymers as multifunctional excipients in drug dosage form technology, Saudi Pharm J., 24(5):525-536, incorporated herein by reference.
• inhalable formulations may have API:carrier ratios of 50:50, 55:45, 60:40, 65:35, 70:30, 75:25, 80:20, 85:15, 90:10, or 95:5.
• Certain inhalable formulations may be pure API with no additional components.
• formulations may include imatinib or salts thereof as the API in amounts greater than 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, or 45%.
• API ratios refer to % w/w.
• micronized imatinib and salts thereof retain crystallinity, even after micronization and suspension for nebulization.
• imatinib formulations of the invention can include less than 50%, less than 25%, less than 20%, less than 10%, less than 9%, less than 8%, less than 7%, less than 6%, less than 5%, less than 4%, less than 3%, less than 2%, or less than 1% amorphous imatinib by mass.
• formulations of the invention include no observable amorphous imatinib content.
• the desired crystalline form and low amorphous content obtained during micronization is carried through to nebulization because the imatinib crystals are not dissolved in the solution to a significant degree.
• inhalable formulations of the invention include imatinib or a salt thereof present in a single crystal form.
• imatinib or a salt thereof may be present at greater than 75%, 80%, 85%, 90%, 95%, or, in preferred embodiments, greater than 99% in a single crystal form by mass.
• the single crystal form may be, for example, type A or type B in various embodiments.
• micronization and particle diameter may be of particular importance for efficient delivery and imatinib may be preferably micronized to a mass median diameter of 2 ⁇ m or less.
• the suspension solution for nebulizer inhalation can be aqueous and doses may be divided into individual containers or compartments for sterile storage prior to use.
• Micronized imatinib particle size can range from about 0.5 ⁇ m to about 5 ⁇ m depending on application. In preferred embodiments the size range is about 1 ⁇ m to about 3 ⁇ m to achieve deep lung penetration.
• the imatinib formulations of the invention may be pharmaceutical compositions for use in treating various conditions of the pulmonary cardiovascular system, such as PAH.
• imatinib is a potent inhibitor of the platelet-derived growth factor receptor (PDGFR) and other signaling kinases.
• the compositions of the invention may be used to treat any disease or disorder that involves inhibition of PDGFR or other kinases sensitive to imatinib.
• compositions of the invention may be used to treat PAH.
• a therapeutically effective amount of a pharmaceutical composition of imatinib according to the various embodiments described herein can be delivered, via inhalation to deliver the desired amount of imatinib compound to the target lung tissue.
• Dosages for treating PAH and other conditions of the pulmonary cardiovascular system may be in the range of between about 1 mg to about 100 mg per dose for inhalation on once, twice or three times per day schedule. About 0.1 mg to about 80 mg of the imatinib or salt thereof may then be deposited within the lung after inhalation. In certain embodiments, about 0.1 to about 1 mg/kg in a dose and may be administered one to four times a day to obtain the desired therapeutic results.
• imatinib formulations of the invention may be used to treat pulmonary hypertension as a result of schistosomiasis. See, for example, Li, et al., 2019, The ABL kinase inhibitor imatinib causes phenotypic changes and lethality in adult Schistosoma japonicum , Parasitol Res., 118(3):881-890; Graham, et al., 2010, Schistosomiasis-associated pulmonary hypertension: pulmonary vascular disease: the global perspective, Chest, 137(6 Suppl):20S-29S, the content of each of which is incorporated herein by reference.
• Imatinib pharmaceutical compositions of the invention may be used to treat lung transplant recipients to prevent organ rejection. See, Keil, et al., 2019, Synergism of imatinib, vatalanib and everolimus in the prevention of chronic lung allograft rejection after lung transplantation (LTx) in rats, Histol Histopathol, 1:18088, incorporated herein by reference.
• LTx chronic lung allograft rejection after lung transplantation
• compositions described herein can be used to treat pulmonary veno-occlusive disease (PVOD).
• PVOD pulmonary veno-occlusive disease
• compounds and methods of the invention may be used to provide greater concentration at the target lung tissue through inhalation along with consistent, predictable pharmacokinetics afforded by low polymorphism and amorphous content.
• the efficient localization of therapeutic compound at the target tissue allows for lower systemic exposure and avoidance of the adverse events associated with prolonged oral administration of imatinib mesylate.
• Methods of the invention can include preparation of imatinib formulations.
• imatinib or salts thereof may be administered via inhalation of nebulized suspensions.
• Imatinib particles for suspension may be obtained via any known method including, in preferred embodiments, jet milling. Jet milling can be used to grind imatinib and, potentially, various additives (e.g., excipients) using a jet (or jets) of compressed air or gas to force collisions between the particles as they transit at near sonic velocity around the perimeter of a toroidal chamber. The size reduction is the result of the high-velocity collisions between particles of the process material. Outputs of the jet mill may allow particles to exit the apparatus once a desired size has been reached. As noted herein, desired particle size may be in the range of about 0.5 ⁇ m to about 5 ⁇ m.
• bulk imatinib may be micronized to the desired size for inhalation via wet milling wherein the imatinib particles are suspended in a slurry and reduced through shearing or impact with a grinding media.
• micronized imatinib obtained using methods of the invention has been found to exhibit no apparent polymorphs other than the designated Type A and very low levels of amorphous content. Accordingly, this can result in improved stability of the drug substance and any drug product upon storage. Single crystal forms such as described may allow for more predictable in vivo behavior and appropriate dosing can be determined.
• an imatinib suspension can be formed.
• the suspension may result from dry micronization followed by suspension of the resulting dry powder or can be obtained as the outcome of a wet milling procedure.
• Imatinib suspensions of micronized crystal forms may be used in nebulized inhalation treatments.
• formulation methods include manipulation of the suspension to prevent dissolution of the imatinib.
• Aqueous solution factors such as pH, ionic strength and dispersing agents may be used to obtain a stable suspension for nebulized inhalation.
• the pH of the aqueous solution may be adjusted to prevent dissolution.
• salt in the aqueous solution may be used to reduce solubility of the imatinib crystals in certain embodiments.
• a dispersing agent or surfactant e.g., Tween 20 or Tween 80
• Tween 20 or Tween 80 e.g., Tween 20 or Tween 80
• excipients can be added to the suspension before nebulization.
• the excipient may be a water-soluble excipient, such as leucine, dileucine, trileucine, trehalose, mannitol, citrate or acetate.
• the excipient may be a water insoluble excipient, such as lecithin, distearylphosphatidylcholine (DSPC) or limonene.
• DSPC distearylphosphatidylcholine
• limonene such insoluble excipients may be dissolved in a non-aqueous medium that is miscible or immiscible with water, thereby creating an emulsion.
• a liposomal dispersion could be created into which the suspended imatinib could be added and homogenized.
• each agent can readily be determined by the skilled person, having regard to typical factors such as the age, weight, sex and clinical history of the patient.
• a suitable daily dose of a compound of the invention will be that amount of the compound which is the lowest dose effective to produce the desired therapeutic effect. Such an effective dose will generally depend upon the factors described above.
• the effective daily dose of the active compound may be administered as one, two, three, four, five, six or more sub-doses administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms.
• compositions of the invention include a “therapeutically effective amount” or a “prophylactically effective amount” of one or more of the compounds of the present invention, or functional derivatives thereof.
• An “effective amount” refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic result, e.g., a diminishment or prevention of effects associated with PAH.
• a therapeutically effective amount of a compound of the present invention or functional derivatives thereof may vary according to factors such as the disease state, age, sex, and weight of the subject, and the ability of the therapeutic compound to elicit a desired response in the subject.
• a therapeutically effective amount is also one in which any toxic or detrimental effects of the therapeutic agent are outweighed by the therapeutically beneficial effects.
• a “prophylactically effective amount” refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired prophylactic result. Typically, since a prophylactic dose is used in subjects prior to, or at an earlier stage of disease, the prophylactically effective amount may be less than the therapeutically effective amount. A prophylactically or therapeutically effective amount is also one in which any toxic or detrimental effects of the compound are outweighed by the beneficial effects.
• Dosage regimens may be adjusted to provide the optimum desired response (e.g. a therapeutic or prophylactic response). For example, a single inhalable bolus may be administered, several divided doses may be administered over time or the dose may be proportionally reduced or increased as indicated by the exigency of the therapeutic situation.
• Actual dosage levels of the active ingredients in the pharmaceutical compositions of this invention may be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular subject, composition, and mode of administration, without being toxic to the patient.
• dosage unit refers to physically discrete units suited as unitary dosages for the mammalian subjects to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
• the specification for the dosage unit forms of the invention are dictated by and directly dependent on (a) the unique characteristics of the compound, and (b) the limitations inherent in the art of compounding such an active compound for the treatment of sensitivity in individuals.
• therapeutically effective amount can be estimated initially either in cell culture assays or in animal models, usually rats, non-human primates, mice, rabbits, dogs, or pigs.
• the animal model is also used to achieve a desirable concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in other subjects.
• the therapeutically effective amount is sufficient to reduce PAH symptoms in a subject. In some embodiments, the therapeutically effective amount is sufficient to eliminate PAH symptoms in a subject.
• Dosages for a particular patient can be determined by one of ordinary skill in the art using conventional considerations, (e.g. by means of an appropriate, conventional pharmacological protocol).
• a physician may, for example, prescribe a relatively low dose at first, subsequently increasing the dose until an appropriate response is obtained.
• the dose administered to a patient is sufficient to effect a beneficial therapeutic response in the patient over time, or, e.g., to reduce symptoms, or other appropriate activity, depending on the application.
• the dose is determined by the efficacy of the particular formulation, and the activity, stability, or half-life of the compounds of the invention or functional derivatives thereof, and the condition of the patient, as well as the body weight or surface area of the patient to be treated.
• the size of the dose is also determined by the existence, nature, and extent of any adverse side-effects that accompany the administration of a particular vector, formulation, or the like in a particular subject.
• Therapeutic compositions comprising one or more compounds of the invention or functional derivatives thereof are optionally tested in one or more appropriate in vitro and/or in vivo animal models of disease, such as models of PAH, to confirm efficacy, tissue metabolism, and to estimate dosages, according to methods well known in the art.
• dosages can be initially determined by activity, stability or other suitable measures of treatment vs. non-treatment (e.g., comparison of treated vs. untreated cells or animal models), in a relevant assay.
• Administration can be accomplished via single or divided doses.
• the aqueous suspension may contain the active material in admixture with excipients suitable for the manufacture of aqueous suspensions.
• excipients are suspending agents dispersing or wetting agents such as a naturally occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such a polyoxyethylene with partial esters derived from fatty acids and hexitol anhydrides, for example polyoxyethylene sorbitan monooleate.
• suspending agents dispersing or wetting agents
• a naturally occurring phosphatide for example lecithin
• condensation products of an alkylene oxide with fatty acids for example polyoxyethylene stearate
• the aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose, mannitol, or trehalose.
• preservatives for example ethyl, or n-propyl p-hydroxybenzoate
• coloring agents for example ethyl, or n-propyl p-hydroxybenzoate
• flavoring agents such as sucrose, mannitol, or trehalose.
• sweetening agents such as sucrose, mannitol, or trehalose.
• Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives.
• composition means a composition comprising a compound as described herein and at least one component comprising pharmaceutically acceptable carriers, diluents, adjuvants, excipients, or vehicles, such as preserving agents, taste-masking agents, fillers, disintegrating agents, wetting agents, emulsifying agents, suspending agents, sweetening agents, flavoring agents, perfuming agents, antibacterial agents, antifungal agents, lubricating agents and dispensing agents, depending on the nature of the mode of administration and dosage forms.
• pharmaceutically acceptable carrier is used to mean any carrier, diluent, adjuvant, excipient, or vehicle, as described herein.
• pharmaceutically acceptable means it is, within the scope of sound medical judgment, suitable for use in contact with the cells of humans and lower animals without undue toxicity, irritation, allergic response, and the like, and are commensurate with a reasonable benefit/risk ratio.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Engineering & Computer Science (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Epidemiology (AREA)
• Pulmonology (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Otolaryngology (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Immunology (AREA)
• Gastroenterology & Hepatology (AREA)
• Zoology (AREA)
• Cardiology (AREA)
• Heart & Thoracic Surgery (AREA)
• Dispersion Chemistry (AREA)
• Biochemistry (AREA)
• Molecular Biology (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicinal Preparation (AREA)

Priority Applications (2)

Applications Claiming Priority (9)

Related Child Applications (1)

Publications (1)

Family

ID=73228465

Family Applications (13)

Family Applications Before (4)

Family Applications After (8)

Country Status (14)

Cited By (1)

Families Citing this family (6)

Citations (3)

Family Cites Families (59)

• 2020
  • 2020-05-14 JO JOP/2021/0305A patent/JOP20210305A1/ar unknown
  • 2020-05-14 EP EP20806763.7A patent/EP3969111A4/en active Pending
  • 2020-05-14 US US16/874,190 patent/US20200360477A1/en active Pending
  • 2020-05-14 MX MX2021014029A patent/MX2021014029A/es unknown
  • 2020-05-14 CN CN202080051359.5A patent/CN114514016A/zh active Pending
  • 2020-05-14 US US16/874,118 patent/US11298355B2/en active Active
  • 2020-05-14 KR KR1020217041312A patent/KR20220050839A/ko unknown
  • 2020-05-14 US US16/874,111 patent/US11229650B2/en active Active
  • 2020-05-14 BR BR112021023014A patent/BR112021023014A2/pt unknown
  • 2020-05-14 US US16/874,122 patent/US11413289B2/en active Active
  • 2020-05-14 AU AU2020274521A patent/AU2020274521A1/en active Pending
  • 2020-05-14 US US16/874,168 patent/US20200360279A1/en not_active Abandoned
  • 2020-05-14 US US16/874,143 patent/US20200360277A1/en active Pending
  • 2020-05-14 CA CA3140641A patent/CA3140641A1/en active Pending
  • 2020-05-14 EP EP20806383.4A patent/EP3968963A4/en active Pending
  • 2020-05-14 US US16/874,128 patent/US20200360276A1/en active Pending
  • 2020-05-14 WO PCT/US2020/032872 patent/WO2020232236A1/en active Application Filing
  • 2020-05-14 JP JP2021568694A patent/JP2022532431A/ja active Pending
  • 2020-05-14 WO PCT/US2020/032874 patent/WO2020232238A1/en active Application Filing
  • 2020-05-14 SG SG11202112719XA patent/SG11202112719XA/en unknown
• 2021
  • 2021-11-14 IL IL288111A patent/IL288111A/he unknown
  • 2021-11-15 ZA ZA2021/09070A patent/ZA202109070B/en unknown
• 2022
  • 2022-01-24 US US17/582,599 patent/US11806349B2/en active Active
  • 2022-03-03 US US17/685,704 patent/US20220184080A1/en active Pending
  • 2022-08-15 US US17/887,866 patent/US11813263B2/en active Active
  • 2022-10-11 US US17/963,607 patent/US20230056721A1/en active Pending
• 2023
  • 2023-10-06 US US18/377,561 patent/US20240108622A1/en active Pending
  • 2023-10-11 US US18/378,949 patent/US20240041879A1/en active Pending

Patent Citations (4)

Also Published As

Similar Documents

Legal Events